OBJECTIVE: Tumor budding is a parameter that is increasingly understood in colorectal carcinomas. We aimed to investigate the relationship between tumor budding, prognostic factors, and survival.
The relationship between tumor budding and survival in colorectal carcinomas
It is known that the pathological stage detected at the time of diagnosis in colorectal carcinoma (CRC) is the most important factor in determining the behavior and clinical course of tumors 1 . Recent studies have shown that patients at the same stage can show different prognosis, and, thus, new prognostic factors are being investigated, such as tumor budding. Tumor budding is thought to be a histological reflection of epithelial-mesenchymal transition (EMT). Cancer cells lose their epithelial properties such as polarity and adhesion during EMT; with the mesenchymal feature, they gain migratory capacity and become more resistant to apoptotic signals. The tumor cells that acquire these properties begin to separate, individually or in small groups, from the main mass 2 . Tumor budding was first described by Imai in 1954 as a morphological feature on the invasive front of the tumor, called tumor sprouting 3 . In 2002, Ueno et al. described tumor budding as a tumor cell or tumor-cell clusters of up to five cells, isolated from the main tumor on the invasive budding were assessed based on the College of American Pathologists' (CAP) colorectal carcinoma reporting protocol. Accordingly, isolated tumor cells separated from the main tumor mass on the invasive front of the tumor or tumor cell clusters of up to 5 cells were classified as tumor budding 7 .
Tumor buds were counted on the invasive margin at an area of 0.785 mm 2 . First, the cases were grouped as 'positive tumor budding' or 'negative tumor budding'. Then, positive tumor budding cases were scored according to the number of tumor buds. Cases with 0-4 tumor buds were scored as low grade, cases with 5-9 as moderate grade, and cases with ≥10 as high grade 4,7 . Routine immunohistochemical examination was not performed according to CAP protocol and ITBCC recommendations. Again, according to the CAP protocol and the recommendations of the ITBCC, an immunohistochemical examination was performed in 30 cases because of the inflammatory reaction surrounding the tumor, which was masking the tumor buds and the tumoral gland destruction by inflammatory cells, which simulates the tumor buds. For these cases, paraffin-embedded tissue blocks were cut at 2.5 µm thickness and immunostained for pan-cytokeratin (panCK) , a marker of epithelial cells that served to highlight areas of tumor budding. SPSS 15.0 for Windows was used for statistical analysis. The ratios were compared by chi-square analysis, and the relationships between ratios were analyzed with Linear-by-Linear Association. The relationships between numerical and ordinal variables were analyzed by Spearman Correlation Analysis. As the numerical variables did not meet the normal distribution condition, the two groups were compared with the Mann Whitney U test. Statistical significance was accepted as p <0.05.
RESULTS
A total of 185 cases were included in the study. Of these, 107 were male, and 78 were female. The mean age of the patients was 60.5 years. Tumors were localized at the ascending colon in 59 cases (31.9%), transverse colon in 11 cases (5.9%), descending colon in 27 cases (14.6%), sigmoid colon in 47 cases (25.4%), and at the rectum in 41 cases (22.2 %) . The tumor diameter was 6.1 cm. The histological subgroup was classic adenocarcinoma in 170 (91.9%) cases and mucinous adenocarcinoma in 15 (8.1%) cases. The histologic grade was low in 30 (16.2%) cases, moderate in 124 front. In the International Tumor Budding Consensus Conference (ITBCC), which was held on April 2016 with participants from 11 different countries, tumor budding was defined as a single tumor cell or a cell cluster of up to 4 tumor cells 4 .
Numerous studies have demonstrated that tumor budding is an independent prognostic factor associated with lymph node metastasis, local recurrence, and survival. The European Society for Medical Oncology (ESMO) and ITBCC guidelines included tumor budding as a criterion for identifying high-risk patient groups 4-6 .
In the present study, we aimed to investigate the presence of tumor budding and the relationship between tumor budding and prognostic factors and survival in patients with colorectal carcinoma.
METHODS

A total of 240 patients who had undergone colorectal surgery at the Haseki Training and Research
Hospital in Istanbul, Turkey, between 2008-2010 were observed. Fifty-five patients were excluded from the study. Among those, 20 patients received neo-adjuvant therapy, the slides of 20 patients could not be found, 14 patients died within a month, and one patient could not be reached for survival information. Colon and rectum resection materials of 185 patients were evaluated retrospectively. All histomorphologic data was reviewed based on the corresponding hematoxylin and eosin (H&E) stained slides, whereas clinical data, tumor localization, tumor size, and surgical margins were obtained from corresponding reports. The survival information of the patients was observed from the records of the hospital information-record system and also from the patients by contacting them.
The H & E stained preparations were re-evaluated for the presence of tumor budding, tumor budding score, tumor type, grade, invasion depth, lymphovascular invasion, perineural invasion, regional lymph node involvement, pT, pN stages. Tumors were grouped as ascending colon, transverse colon, descending colon, sigmoid colon, and rectum according to their location.
We evaluated the histological subtypes following the World Health Organization (WHO) classification. Tumor invasion depth and lymph node evaluation were performed according to the 8 th edition of the American Cancer Committee (AJCC) tumor-nod-metastasis (TNM) classification. The presence and score of tumor (67%, and high in 31 (16.8%). Lymphovascular invasion was detected in 110 (59.5%) cases and perineural invasion in 60 (32.6%) cases. A total of 2 cases (1.1%) were evaluated as pT1, 22 cases (11.9%) as pT2, 125 (67.6%) as pT3, and 36 (19.5%) as pT4. The number of lymph nodes was between 0-44, and the average number was 14. The lymph node involvement stage was N0 in 99 (53.5%) cases, N1a in 23 (12.4%) cases, N1b in 29 (15%), N2a in 19 (10.3%), and N2b in 15 (8.1%) cases. The mean follow-up period was 68.7 months and ranged from 2 to 108 months. A total of 104 cases (56.2%) were alive, and 81 (43.8%) died.
Tumor budding was found in 91 (49.2%) cases; 49 cases (26.5%) with low grade, 17 (9.2%) with moderate, and 25 (13.5%) with high-grade tumor budding.
No significant difference was observed between tumor budding and sex, age, tumor localization, tumor size, histological type of tumor, histological grade of the tumor, or pathologic T stage (p >0.05). Tumor budding was detected in 63 (69.2%) of 110 cases with lymphovascular invasion and 39 (42.9%) of 60 cases with perineural invasion. Both were significant (p=0.008 p=0.003), (Table 1) .
There were significant differences between the cases with and without tumor budding in terms of pathologic lymph node stages (p = 0.026). In addition, the rate of patients with tumor budding was lower than those without metastatic lymph nodes (p = 0.0049).
Also, the relationship between tumor budding and cumulative survival was significant; 48 (52.7%) of the 91 cases with tumor budding died, and 43 (47.3%) were still alive. The mortality rate of patients with tumor budding was significant (p = 0.016), as shown in Table 1 .
The relationship between the tumor budding score and histological grade, lymphovascular invasion, perineural invasion, pathological lymph node stage and mortality rates were significant (p = 0.007, p <0.001, p <0.001, p = 0.002, p = 0.001). As the tumor budding scores increased, lymphovascular invasion, perineural invasion, pN, and mortality rates increased too. As the tumor budding score increased, the rates of those with histological grade 1 decreased ( Table 2) .
The tumor budding score was found to be positively correlated with the number of metastatic lymph nodes, amd negatively correlated with the follow-up times (p = 0.011 p = 0.001)
The cumulative survival rate of patients with tumor budding was significantly lower than of those without tumor budding (p = 0.023) ( Table 3) .
There was a significant difference in the survival rates of tumor budding scores (p <0.001). The survival rates of patients with high tumor budding were significantly lower than those without tumor budding, or with low and moderate tumor budding scores. (p <0.001 p <0.001 p = 0.021) ( Table 3 ). 
DISCUSSION
The number of colorectal carcinoma cases ranks 3 rd worldwide. Every year, 1.4 million people are diagnosed with CRC, and more than 600 thousand people lose their lives due to the disease 8, 9 . After 50 years of age, it increases significantly, reaching the highest incidence in the second half of the eighth decade 10 .
The most important independent prognostic factor in CRCs is the stage of the tumor 1 . However, the fact that patients at the same pathological stage in the postoperative period present differences in terms of local recurrence and invasion suggests that pathological staging (TNM) is insufficient in these patients 11 . The situation required the investigation of biological, molecular, and morphological factors that may be related to the aggressive behavior of the tumor in the cancer tissue. Recent studies have focused on tumor budding, which is thought to be the first step of the metastatic process, among these morphological factors 12-14 .
In the literature, there is no significant relationship between tumor budding, age, sex and localization, diameter, or histologic subtype of tumor; we did not find any significant relationship either 5,12,15-21 .
The relationship between tumor budding and the degree of histological differentiation of the tumor was not significant. However, the relationship between the tumor budding score and the degree of histological differentiation revealed a significant decrease in the rate of good differentiation. The relationship of tumor budding with pathological T stages has been investigated in many studies, and it was found that tumor budding is associated with advanced stages 2,15-18,21-23 . Koelzer et al. 18 showed no significant relationship with pT. In our study, we found more tumor budding in pT3 stage, but this was not significant.
Few studies have demonstrated a significant correlation between tumor budding and perineural invasion 18,23, 24 . In our study, a significant correlation was found between the presence of tumor budding and the score of tumor budding and perineural invasion.
A significant relationship between tumor budding and lymphovascular invasion has been shown in most studies 2,15-18,21,23, 24 . In our study, the relationship between tumor budding and lymphovascular invasion was significant. In addition, as the degree of tumor budding increases, the rate of cases with lymphovascular invasion increases too, so there is a significant relationship between the tumor budding score and lymphovascular invasion.
Numerous studies have examined the relationship of tumor budding with lymph node metastasis. In 2012, Kye et al. 25 compared the relationship between regional lymph node metastasis and all other prognostic factors in 55 patients with stage pT1; among all parameters, only tumor budding was found to be an independent prognostic factor for lymph node metastasis. In our study, the relationship of tumor budding with metastatic lymph node number and lymph node stage was significant. In addition, the relationship between the tumor budding score and pN stage is significant; as the degree of tumor budding increases, the pN is also increased.
As the prognostic importance of tumor budding was understood, the number of studies investigating the relationship with survival also increased. All these studies have shown that the presence of tumor budding is associated with significant poor clinical outcomes and shorter survival time.
In the study by Ohtsuki et al. 23 , the disease-free survival rate was 40.9% for cases with tumor budding and 75.1% in cases without tumor budding. Rogers et al. 26 reported that tumor budding was an independent prognostic factor related to cancer-related death in univariate and multivariate analyses. When we look at the relationship between tumor budding and cumulative survival, of the 91 cases with tumor budding, 48 (52.7%) died, and 43 (47.3%) were still alive. The mortality rate of patients with tumor budding was significant. There was a significant correlation between the tumor budding degrees and follow-up periods in patients with tumor budding. The cumulative survival rate of patients with tumor budding was significantly lower than those without tumor budding. In addition, the relationship between the score of tumor budding and cumulative survival is significant. The cumulative survival rate of patients with high tumor budding rates is significantly lower than other scores and no tumor budding.
CONCLUSION
In our study, the relationship between tumor budding and survival is very strong. Considering these findings and the literature, the prognostic significance of tumor budding becomes clear and should be stated in pathology reports.
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